WO2010141690A3 - Indane analogs and use as pharmaceutical agents and process of making - Google Patents

Indane analogs and use as pharmaceutical agents and process of making Download PDF

Info

Publication number
WO2010141690A3
WO2010141690A3 PCT/US2010/037216 US2010037216W WO2010141690A3 WO 2010141690 A3 WO2010141690 A3 WO 2010141690A3 US 2010037216 W US2010037216 W US 2010037216W WO 2010141690 A3 WO2010141690 A3 WO 2010141690A3
Authority
WO
WIPO (PCT)
Prior art keywords
indane
disease
analogs
making
pharmaceutical agents
Prior art date
Application number
PCT/US2010/037216
Other languages
French (fr)
Other versions
WO2010141690A2 (en
Inventor
Kenneth J. Ingold
Mary Katherine Delmedico
Original Assignee
Dara Biosciences, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dara Biosciences, Inc. filed Critical Dara Biosciences, Inc.
Publication of WO2010141690A2 publication Critical patent/WO2010141690A2/en
Publication of WO2010141690A3 publication Critical patent/WO2010141690A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
    • C07D263/30—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D263/32—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

This invention relates to novel indane analogues that are useful in the treatment of diseases and disorders such as treating and/or preventing diabetes and related disorders such as Syndrome X, impaired glucose tolerance, impaired fasting glucose, and hyperinsulinemia obesity, atherosclerotic disease, dyslipidemia, and related disorders such as hypertriglyceridemia, low HDL cholesterol, and hypercholesteremia, cardiovascular disease, cerebrovascular disease, psoriasis, or Alzheimer's disease. The invention also relates to intermediates useful in preparation of indane acetic derivatives and to methods of preparation.
PCT/US2010/037216 2009-06-04 2010-06-03 Indane analogs and use as pharmaceutical agents and process of making WO2010141690A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US18414909P 2009-06-04 2009-06-04
US61/184,149 2009-06-04

Publications (2)

Publication Number Publication Date
WO2010141690A2 WO2010141690A2 (en) 2010-12-09
WO2010141690A3 true WO2010141690A3 (en) 2011-01-27

Family

ID=43298504

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2010/037216 WO2010141690A2 (en) 2009-06-04 2010-06-03 Indane analogs and use as pharmaceutical agents and process of making

Country Status (2)

Country Link
TW (1) TW201102372A (en)
WO (1) WO2010141690A2 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104768544B (en) * 2012-08-09 2017-06-16 迪纳米斯治疗公司 Composition including meglumine or its salt is preparing the application in reducing or preventing the increased medicine of triglyceride levels

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002080935A1 (en) * 2001-04-04 2002-10-17 Ortho Mcneil Pharmaceutical, Inc. Combination therapy comprising glucose reabsorption inhibitors and retinoid-x receptor modulators
WO2003011842A1 (en) * 2001-07-27 2003-02-13 Bayer Pharmaceuticals Corporation Indane acetic acid derivatives and their use as pharmaceutical agents, intermediates, and method of preparation
EP1644320B1 (en) * 2003-07-03 2008-01-16 Eli Lilly And Company Indane derivates as muscarinic receptor agonists

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002080935A1 (en) * 2001-04-04 2002-10-17 Ortho Mcneil Pharmaceutical, Inc. Combination therapy comprising glucose reabsorption inhibitors and retinoid-x receptor modulators
WO2003011842A1 (en) * 2001-07-27 2003-02-13 Bayer Pharmaceuticals Corporation Indane acetic acid derivatives and their use as pharmaceutical agents, intermediates, and method of preparation
EP1644320B1 (en) * 2003-07-03 2008-01-16 Eli Lilly And Company Indane derivates as muscarinic receptor agonists

Also Published As

Publication number Publication date
TW201102372A (en) 2011-01-16
WO2010141690A2 (en) 2010-12-09

Similar Documents

Publication Publication Date Title
WO2007109024A3 (en) Thiazolidinedione analogues for the treatment of metabolic inflammation mediated disease
CL2007003755A1 (en) COMPOUNDS DERIVED FROM INDOL; PHARMACEUTICAL COMPOSITION THAT INCLUDES SUCH COMPOUNDS; AND ITS USE IN THE TREATMENT OF AFFECTIONS OR DISORDERS MEDIATED BY S1P1 RECEPTORS SUCH AS AUTOIMMUNITY DISEASES, ASTHMA, NEUROPATHY, ARTHRITIS, DIABE
WO2009153496A3 (en) Ppar agonist compounds and preparation and uses thereof for treating diabetes and/or dyslipidemia
WO2007104789A3 (en) Amylin derivatives
NZ593813A (en) Glucagon analogues
CL2013001340A1 (en) Compounds derived from isoindol-amide, pyrrolo-pyridin-amide and pyrrolo-pyrimimidin-amide, nampt and rock inhibitors; pharmaceutical composition; and method to treat hyperetension, chronic heart failure, atherosclerosis, asthma, Alzheimer's disease, parkinson's disease and glaucoma, among other diseases.
WO2008008359A3 (en) Benzofuro-and benzothienopyryimidine modulators of the histamine h4 receptor
MX2015010935A (en) Antidiabetic bicyclic compounds.
BRPI0821039B8 (en) solid forms of 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl)cyclopropanecarboxamido)-3-methylpyridin-2-yl)benzoic acid, process for their preparation , pharmaceutical compositions comprising the same and uses
WO2011007230A3 (en) Lupeol-type triterpene derivatives as antivirals
CL2007002288A1 (en) COMPOUNDS DERIVED FROM CONDENSED IMIDAZOL-AMINA, INHIBITORS OF BETA-SECRETASA; PREPARATION PROCESS; PHARMACEUTICAL COMPOSITION, USEFUL FOR THE TREATMENT, PREVENTION OR IMPROVEMENT OF DISEASES SUCH AS ALZHEIMER'S DISEASE, DETERIORATION
CL2007001023A1 (en) COMPOUNDS DERIVED FROM CROMEN-2-ONA; PREPARATION PROCESS; PHARMACEUTICAL COMPOSITION; PHARMACEUTICAL COMBINATION, USEFUL FOR THE TREATMENT OR PREVENTION OF DISORDERS OR DISEASES MEDIATED BY T-LYMPHOCYTES, SUCH AS REUMATOID ARTHRITIS AND DIABE
MX2009008787A (en) 2-aminopyrimidine modulators of the histamine h4 receptor.
MX2015001500A (en) Antidiabetic tricyclic compounds.
CL2007003502A1 (en) COMPOUNDS DERIVED FROM PYRIMIDIN-AMINA, JNK MODULATORS; PREPARATION PROCESS; PHARMACEUTICAL COMPOSITIONS; AND USE FOR THE TREATMENT OF REUMATOID ARTHRITIS, ASTHMA, TYPE II DIABETES, ALZHEIMER'S DISEASE, PARKINSON'S DISEASE AND APOPLEJIA.
WO2008152093A3 (en) Diaminopyrimidines as modulators of the ep2 receptor
MY188182A (en) Acylated glucagon analogues
EP2799447A3 (en) Glucagon analogues
HK1098125A1 (en) Indane acetic acid compounds
WO2008070692A8 (en) Bicyclic compounds and use as antidiabetics
EP1910321A4 (en) New compounds, process for their preparation, intermediates, pharmaceutical compositions and their use in the treatment of 5-ht6 mediated disorders such as alzheimer's disease, cognitive disorders, cognitive impairment associated with schizophrenia, obesity and parkinson's disease
WO2009033561A8 (en) Substituted 6-phenylnicotinic acids and the use thereof
CL2008000738A1 (en) COMPOUNDS DERIVED FROM MALONAMIDE; PROCESS FOR THE PREPARATION OF SUCH COMPOUNDS; PHARMACEUTICAL COMPOSITION THAT INCLUDES SUCH COMPOUNDS; AND ITS USE FOR THE TREATMENT OF DEPRESSION, PARKINSON AND ALZHEIMER'S DISEASE, BETWEEN OTHER DISEASES
ECSP11011051A (en) NEW COMPOUNDS 578
CL2008002506A1 (en) Compounds derived from substituted benzimidazole, preparation process, pharmaceutical composition, useful in the treatment of diseases modulated with antagonists of the fxr receptor, in particular for the treatment of increased levels of lipids and / or cholesterol, atherosclerotic disease, diabetes, cancer, parkinson's , Alzheimer's.

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 10784075

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 10784075

Country of ref document: EP

Kind code of ref document: A2